SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-224610
Filing Date
2022-08-19
Accepted
2022-08-19 07:05:33
Documents
14
Period of Report
2022-08-19
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d367288d8k.htm   iXBRL 8-K 24801
2 EX-99.1 d367288dex991.htm EX-99.1 77441
6 GRAPHIC g367288g0819074005770.jpg GRAPHIC 2867
  Complete submission text file 0001193125-22-224610.txt   243625

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA axsm-20220819.xsd EX-101.SCH 2842
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE axsm-20220819_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE axsm-20220819_pre.xml EX-101.PRE 11252
8 EXTRACTED XBRL INSTANCE DOCUMENT d367288d8k_htm.xml XML 3356
Mailing Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007
Business Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

IRS No.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37635 | Film No.: 221178926
SIC: 2834 Pharmaceutical Preparations